Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ischemic Heart Disease
  Free Subscription

Articles published in
Lancet
    July 2026
  1. RUEL M, Nambala S, Guo MH, Verevkin A, et al
    Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.
    Lancet. 2026 Jul 31:S0140-6736(26)01288-2. doi: 10.1016/S0140-6736(26)01288.
    >> Share

  2. ZHU Y, Gaudino M, Zhao Q
    Physiology-guided coronary artery bypass grafting in valve surgery - Authors' reply.
    Lancet. 2026;408:218.
    >> Share

  3. MAGOULIOTIS DE, Sicouri S, Ramlawi B
    Physiology-guided coronary artery bypass grafting in valve surgery.
    Lancet. 2026;408:217-218.
    >> Share

  4. LIP GYH, Kuzma L
    Combination antithrombotic therapy in atrial fibrillation after coronary interventions: shorter duration, more safety?
    Lancet. 2026 Jul 15:S0140-6736(26)00747-6. doi: 10.1016/S0140-6736(26)00747.
    >> Share

  5. SOTOMI Y, Kozuma K, Higuchi Y, Nakazawa G, et al
    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
    Lancet. 2026 Jul 15:S0140-6736(26)00665-3. doi: 10.1016/S0140-6736(26)00665.
    >> Share

    May 2026
  6. ESCANED J, Mejia-Renteria H
    Microvascular dysfunction in atherosclerotic coronary disease.
    Lancet. 2026 May 21:S0140-6736(26)00862-7. doi: 10.1016/S0140-6736(26)00862.
    >> Share

  7. LEE JM, Lee SH, Gim DH, Lee SY, et al
    Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea.
    Lancet. 2026 May 21:S0140-6736(26)00666-5. doi: 10.1016/S0140-6736(26)00666.
    >> Share

    April 2026
  8. ZENG G, Bidel Z, Yang Q, Canoy D, et al
    Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
    Lancet. 2026;407:1626-1638.
    >> Share

  9. MANGALESH S, Theodoropoulos P, Chi KY, Nanna MG, et al
    Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.
    Lancet. 2026;407:1601.
    >> Share

  10. TONDT J, Chinchilli VM
    Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.
    Lancet. 2026;407:1601.
    >> Share

  11. DEANFIELD J, Emerson SS, Rasmussen S, Stensen S, et al
    Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.
    Lancet. 2026;407:1601-1602.
    >> Share

  12. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    >> Share

  13. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    >> Share

  14. SUN Y, Guo X
    Cardiovascular benefit of blood-pressure lowering in chronic kidney disease.
    Lancet. 2026;407:1578-1580.
    >> Share

  15. VAN DER BIJL P, Bax JJ
    Contemporary non-invasive imaging for coronary artery disease - Authors' reply.
    Lancet. 2026;407:1425.
    >> Share

  16. HUNYOR I, Wilcox I, O'Sullivan J
    Contemporary non-invasive imaging for coronary artery disease.
    Lancet. 2026;407:1424.
    >> Share

  17. ZHENG H
    Contemporary non-invasive imaging for coronary artery disease.
    Lancet. 2026;407:1424.
    >> Share

  18. HOLCK EN, Holm NR, Hildick-Smith D, Lindsay MM, et al
    Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.
    Lancet. 2026;407:1374-1382.
    >> Share

    March 2026
  19. CHIARITO M, Tartaglia F
    Moving beyond aspirin after percutaneous coronary intervention: 10-year results from the HOST-EXAM trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00562-3. doi: 10.1016/S0140-6736(26)00562.
    >> Share

  20. GAROT P, Akodad M
    Coronary revascularisation before TAVI.
    Lancet. 2026 Mar 29:S0140-6736(26)00597-0. doi: 10.1016/S0140-6736(26)00597.
    >> Share

  21. DELEWI R, Aarts HM, Broeze GM, Hemelrijk KI, et al
    Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00308-9. doi: 10.1016/S0140-6736(26)00308.
    >> Share

  22. KANG J, Park S, Yang HM, Shin ES, et al
    Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00422-8. doi: 10.1016/S0140-6736(26)00422.
    >> Share

  23. ZHU Y, Cheng Z, Zhao Y, Han L, et al
    Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-
    Lancet. 2026;407:1161-1170.
    >> Share

  24. STEINHAUER R, Xu JYH, Blumenthal RS, Troy AL, et al
    Early atheroma prevention: a cost-effective approach to healthy cardiovascular ageing.
    Lancet. 2026 Mar 16:S0140-6736(26)00419-8. doi: 10.1016/S0140-6736(26)00419.
    >> Share

    February 2026
  25. VALGIMIGLI M, Gragnano F, Giacoppo D
    Clopidogrel versus aspirin for coronary artery disease - Authors' reply.
    Lancet. 2026;407:853-854.
    >> Share

  26. IBRAHIM A, Shalabi L, Ando G
    Clopidogrel versus aspirin for coronary artery disease.
    Lancet. 2026;407:853.
    >> Share

  27. DELLO RUSSO C, Venetucci L, Ramlogan R, Gagliardi D, et al
    Clopidogrel versus aspirin for coronary artery disease.
    Lancet. 2026;407:852-853.
    >> Share

  28. COLLI A, Casazza G, Gluud C
    Clopidogrel versus aspirin for coronary artery disease.
    Lancet. 2026;407:851-852.
    >> Share

  29. XIONG Y, Alemseged F, Cao Z, Schwamm LH, et al
    Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.
    Lancet. 2026 Feb 5:S0140-6736(25)02633-9. doi: 10.1016/S0140-6736(25)02633.
    >> Share

  30. TSIVGOULIS G, Palaiodimou L, Turc G
    Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion.
    Lancet. 2026 Feb 5:S0140-6736(26)00139-X. doi: 10.1016/S0140-6736(26)00139.
    >> Share

    January 2026
  31. WENZL FA, Ow KW, Velders MA, Tyrer F, et al
    Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.
    Lancet. 2026;407:515-528.
    >> Share

  32. LIU JE, Feldman DN
    Cancer and acute coronary syndrome: from risk assessment to personalised clinical decision making.
    Lancet. 2026;407:474-475.
    >> Share

  33. KELSHIKER MA, Bachtiger P, Petri CF, Nakhare S, et al
    Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.
    Lancet. 2026 Jan 28:S0140-6736(25)02156-7. doi: 10.1016/S0140-6736(25)02156.
    >> Share

  34. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    >> Share

  35. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
    Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
    >> Share

    December 2025
  36. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
    TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
    Lancet. 2025;404:2593-2602.
    >> Share

  37. TARANTINI G, Cardaioli F
    TAVI and PCI: redefining treatment for aortic stenosis and complex coronary artery disease.
    Lancet. 2025;404:2492-2493.
    >> Share

  38. TAVILDARI A, Dallenbach L, Sierro C, Jovic D, et al
    45-year follow-up after Gruntzig's coronary angioplasty.
    Lancet. 2025;406:2750.
    >> Share

    November 2025
  39. VAN DER BIJL P, Gulati M, Saraste A, Marwick T, et al
    Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease.
    Lancet. 2025;406:2577-2587.
    >> Share

  40. LEE JM
    Complete revascularisation in patients with acute myocardial infarction.
    Lancet. 2025 Nov 9:S0140-6736(25)02243-3. doi: 10.1016/S0140-6736(25)02243.
    >> Share

  41. MEHTA SR, Tiong DTW, Bohm F, Ramasundarahettige C, et al
    Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.
    Lancet. 2025 Nov 9:S0140-6736(25)02170-1. doi: 10.1016/S0140-6736(25)02170.
    >> Share

  42. SEFEROVIC PM, Polovina MM
    New perspectives on semaglutide in cardiovascular disease.
    Lancet. 2025;406:2198-2200.
    >> Share

  43. CAPODANNO D
    Three-month dual antiplatelet therapy after percutaneous coronary intervention: time for a new standard.
    Lancet. 2025;406:2196-2198.
    >> Share

  44. KANG J, Park KW, Han JK, Hwang D, et al
    Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
    Lancet. 2025;406:2244-2256.
    >> Share

    October 2025
  45. GAO C, Onuma Y, Serruys PW, Tao L, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions - Authors' reply.
    Lancet. 2025;406:1951-1952.
    >> Share

  46. RISSANEN TT, Eccleshall S, Jeger R, Latib A, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1950-1951.
    >> Share

  47. GURGOGLIONE FL, Cortese B
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1950.
    >> Share

  48. SPAULDING C, Eccleshall S, Krackhardt F, Urban P, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1949-1950.
    >> Share

  49. LIM PO
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1949.
    >> Share

  50. ZHOU T
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1948-1949.
    >> Share

  51. HON JJ, Hon JKF
    Plant-based diets for coronary artery disease prevention.
    Lancet. 2025;406:1946-1947.
    >> Share

  52. DEANFIELD J, Lincoff AM, Kahn SE, Emerson SS, et al
    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
    Lancet. 2025 Oct 22:S0140-6736(25)01375-3. doi: 10.1016/S0140-6736(25)01375.
    >> Share

    August 2025
  53. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
    beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
    >> Share

  54. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01529-6. doi: 10.1016/S0140-6736(25)01529.
    >> Share

  55. BYRNE RA, Coughlan JJ
    Immediate or staged complete revascularisation in patients with ST segment elevation myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01680-0. doi: 10.1016/S0140-6736(25)01680.
    >> Share

  56. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    >> Share

  57. VERMA S, Leiter LA, Teoh H, Mancini GBJ, et al
    Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01633-2. doi: 10.1016/S0140-6736(25)01633.
    >> Share

  58. GAUDINO M, Sandner S
    Evolocumab for prevention of coronary artery bypass failure: timing is everything.
    Lancet. 2025 Aug 28:S0140-6736(25)01718-0. doi: 10.1016/S0140-6736(25)01718.
    >> Share

  59. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    >> Share

  60. VALGIMIGLI M, Choi KH, Giacoppo D, Gragnano F, et al
    Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
    Lancet. 2025 Aug 28:S0140-6736(25)01562-4. doi: 10.1016/S0140-6736(25)01562.
    >> Share

  61. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    >> Share

  62. LAM CSP, Cader FA, Chew NWS, Chow CK, et al
    Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission.
    Lancet. 2025 Aug 25:S0140-6736(25)01494-1. doi: 10.1016/S0140-6736(25)01494.
    >> Share

  63. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    >> Share

    July 2025
  64. VRINTS C, Andreotti F
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:335.
    >> Share

  65. ANDERSEN BK, Escaned J, Christiansen EH, Holm NR, et al
    QFR vs FFR for intermediate coronary stenosis - Authors' reply.
    Lancet. 2025;406:335-336.
    >> Share

  66. KOMAMURA K, Miyake H, Kobayashi K, Ishiki R, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    >> Share

  67. ONUMA Y, Tsai TY, Sharif F, Wykrzykowska J, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    >> Share

  68. ZHU Q, Cheng Y, Wang S
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333-334.
    >> Share

  69. RODRIGUEZ-GRANILLO GA, Garcia-Garcia HM, Thierer J
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333.
    >> Share

    June 2025
  70. CONRAD N, Rahimi K, McMurray JJV, Casadei B, et al
    The changing spectrum of cardiovascular diseases.
    Lancet. 2025 Jun 9:S0140-6736(25)00990-0. doi: 10.1016/S0140-6736(25)00990.
    >> Share

  71. THE LANCET
    From innovation to impact in cardiovascular disease.
    Lancet. 2025;405:2023.
    >> Share

    May 2025
  72. LEE SJ, Kim BK
    Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease.
    Lancet. 2025 May 5:S0140-6736(25)00827-X. doi: 10.1016/S0140-6736(25)00827.
    >> Share

    April 2025
  73. HUANG C
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1463.
    >> Share

  74. VALGIMIGLI M, Hong SJ, Gragnano F, Hong MK, et al
    Ticagrelor monotherapy for acute coronary syndromes - Authors' reply.
    Lancet. 2025;405:1463-1464.
    >> Share

  75. APOSTOLOS A, Tsigkas G
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1462-1463.
    >> Share

  76. GUO C, Shan D, Liu Z, He F, et al
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1461-1462.
    >> Share

  77. ONIDA S, Davies AH
    Cardiovascular risk assessment in venous disease?
    Lancet. 2025;405:1141-1142.
    >> Share

    March 2025
  78. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    >> Share

  79. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    >> Share

  80. HU X, Zhang J, Yang S, Jiang J, et al
    Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504.
    >> Share

  81. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    >> Share

  82. TAM DY, Lee G, Chikwe J
    Fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting: please mind the gap.
    Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583.
    >> Share

  83. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    >> Share

  84. ROSSELLO X, Kristensen AMD
    Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice.
    Lancet. 2025 Mar 28:S0140-6736(25)00562-8. doi: 10.1016/S0140-6736(25)00562.
    >> Share

  85. ZAMAN S, Wasfy JH, Kapil V, Ziaeian B, et al
    The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
    Lancet. 2025 Mar 25:S0140-6736(25)00055-8. doi: 10.1016/S0140-6736(25)00055.
    >> Share

  86. THE LANCET
    Rethinking coronary artery disease: a call to action.
    Lancet. 2025 Mar 25:S0140-6736(25)00497-0. doi: 10.1016/S0140-6736(25)00497.
    >> Share

  87. CHANDRASHEKHAR Y, Mensah G, Narula J
    From coronary artery disease to atherosclerotic coronary artery disease: what is in a name?
    Lancet. 2025 Mar 25:S0140-6736(25)00563-X. doi: 10.1016/S0140-6736(25)00563.
    >> Share

  88. WILSON C
    Nancy Brown: using advocacy to advance cardiovascular health.
    Lancet. 2025;405:688.
    >> Share

    February 2025
  89. XU C
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:545.
    >> Share

  90. CHAN K, Neubauer S, Channon KM, Deanfield J, et al
    Inflammatory cardiovascular events and coronary artery disease - Authors' reply.
    Lancet. 2025;405:545-546.
    >> Share

  91. ZHAO K, Chen L, Sun Z
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544.
    >> Share

  92. NURMOHAMED NS, Beverloo CYY, Kraaijenhof JM, Stroes ESG, et al
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544-545.
    >> Share

    January 2025
  93. WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al
    Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
    Lancet. 2025;405:329-337.
    >> Share

    November 2024
  94. LUSEBRINK E, Binzenhofer L, Adamo M, Lorusso R, et al
    Cardiogenic shock.
    Lancet. 2024;404:2006-2020.
    >> Share

    October 2024
  95. ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al
    Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
    Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175.
    >> Share

  96. BECKER LM, Swaans MJ
    Present and future of functional measurements in coronary revascularisation.
    Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367.
    >> Share

  97. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
    Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227.
    >> Share

  98. CAPODANNO D
    Coronary stenting with bioadaptors.
    Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359.
    >> Share

    September 2024
  99. THIELE H, Moller JE, Henriques JPS, Bogerd M, et al
    Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
    Lancet. 2024;404:1019-1028.
    >> Share

  100. NORDESTGAARD BG, Langsted A
    Lipoprotein(a) and cardiovascular disease.
    Lancet. 2024 Sep 12:S0140-6736(24)01308-4. doi: 10.1016/S0140-6736(24)01308.
    >> Share

    August 2024
  101. KRUMHOLZ HM, Geraldes F, Wilson C, Horton R, et al
    The Lancet-JACC collaboration: advancing cardiovascular health.
    Lancet. 2024;404:833-834.
    >> Share

  102. JENTZER JC, Hibbert B
    Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock.
    Lancet. 2024 Aug 30:S0140-6736(24)01588-5. doi: 10.1016/S0140-6736(24)01588.
    >> Share

  103. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    >> Share

  104. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    >> Share

  105. GAO C, He X, Ouyang F, Zhang Z, et al
    Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
    Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594.
    >> Share

  106. MCENTEGART MB, Kirtane AJ
    How feasible is a cage-free solution for de novo coronary artery disease?
    Lancet. 2024 Aug 30:S0140-6736(24)01696-9. doi: 10.1016/S0140-6736(24)01696.
    >> Share

  107. VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al
    De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
    Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616.
    >> Share

  108. STEFANINI GG, Oliva A
    Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?
    Lancet. 2024 Aug 30:S0140-6736(24)01678-7. doi: 10.1016/S0140-6736(24)01678.
    >> Share

  109. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    >> Share

    June 2024
  110. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    >> Share

  111. GAO Y, Li Z, Liu M, Tian J, et al
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    >> Share

  112. YU Z, Li G
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    >> Share

  113. ZEYMER U, Freund A, Hochadel M, Schneider S, et al
    VA-ECMO for infarct-related cardiogenic shock - Authors' reply.
    Lancet. 2024;403:2487-2488.
    >> Share

  114. LI Y
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    >> Share

  115. DALZELL JR
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    >> Share

  116. WANG G, Guan J, Liu Z
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2485.
    >> Share

  117. KELLY P, Lemmens R, Weimar C, Walsh C, et al
    Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
    >> Share

    May 2024
  118. CHAN K, Wahome E, Tsiachristas A, Antonopoulos AS, et al
    Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.
    Lancet. 2024 May 29:S0140-6736(24)00596-8. doi: 10.1016/S0140-6736(24)00596.
    >> Share

  119. COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al
    Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
    Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921.
    >> Share

    April 2024
  120. FOLEY MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, et al
    Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
    Lancet. 2024;403:1543-1553.
    >> Share

  121. MONTI CB, Palmisano A
    Coronary sinus reducer: a new hope for refractory angina?
    Lancet. 2024;403:1514-1515.
    >> Share

  122. LI X, Ge Z, Kan J, Anjum M, et al
    Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
    >> Share

  123. DEN DEKKER WK
    Is intravascular imaging the future of percutaneous coronary intervention?
    Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
    >> Share

  124. GE Z, Kan J, Gao X, Raza A, et al
    Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
    >> Share

  125. STEINER-GAGER GM, Siller-Matula JM
    Abbreviated dual antiplatelet therapy after acute coronary syndrome.
    Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586.
    >> Share

  126. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
    Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
    >> Share

  127. BOROVAC JA
    Percutaneous coronary intervention for non-obstructive vulnerable plaques.
    Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
    >> Share

    March 2024
  128. RIDKER PM, Bhatt DL, Nissen SE
    Inflammation, infection, and cardiovascular risk - Authors' reply.
    Lancet. 2024;403:1025-1026.
    >> Share

  129. SHARMA S, Sharma R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1024-1025.
    >> Share

  130. GOLDMAN M, Bondue A, Cogan E
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023.
    >> Share

  131. GOLDSTEIN MR, Mascitelli L
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023-1024.
    >> Share

  132. DROZD M, Cubbon R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022-1023.
    >> Share

  133. PAREEK A, Chandurkar N, Naidu K, Raut V, et al
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022.
    >> Share

  134. STRANDBERG TE, Kovanen PT, Gylling H
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021.
    >> Share

  135. LIN GM, Huang WC, Han CL
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021-1022.
    >> Share

    February 2024
  136. LEE ZS, Ryan N
    Intravascular imaging in percutaneous coronary intervention.
    Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
    >> Share

  137. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016